Published: 22 January 2015
Author(s): Luis Castilla-Guerra, Maria del Carmen Fernandez-Moreno
Section: Letter to the Editor

Treatment with statins reduces the rate of cardiovascular events in high-risk patients, but residual risk persists. At least part of that risk may be attributable to atherogenic dyslipidemia characterized by low HDLc (≤40mg/dL) and high triglycerides (triglycerides ≥150mg/dL) [1]. There is mounting evidence that atherogenic dyslipidemia is an independent predictor of high cardiovascular risk and stroke.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.